NCT07752238Recruiting
Diagnostic Prediction Model for De Novo Metastatic Breast Cancer
Development of a Diagnostic Prediction Model for de Novo Metastatic Breast Cancer Using Routinely Available Baseline Parameters
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to create a tool to estimate the risk of macroscopic distant tumor spread in women with newly diagnosed breast cancer. The main question it aims to answer is: • Can a model, which combines routine medical information collected at diagnosis, accurately predict if a patient has metastasis large enough to be found during systemic imaging? Researchers will review the past medical records of participants who were treated at a university hospital. Because this study looks at past data, participants will not be asked to do any new tasks, take new tests, or change their medical care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 925 (estimated)
- First submitted
- 3 Aug 2026
- Start date
- 10 Aug 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Markusovszky University Teaching Hospital os County Vas
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07752238
What you commit to
- Study type: Observational
- Planned participants: 925
- From 10 Aug 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -Absence of baseline systemic staging.
Who the study is looking for
- Female sex, aged 18 years or older.
- Newly diagnosed invasive breast cancer.
- Case reviewed by the Multidisciplinary Tumour Board at the study site during the inclusion period (between October 1, 2018, and July 31, 2025).
- No history of prior or synchronous invasive malignancies, except for synchronous bilateral breast cancer.
- Intent for primary treatment and clinical management at the study site.
- Availability of longitudinal clinical records throughout the 12-month follow-up period or until death.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Markusovszky University Teaching Hospital Coordinator of this site? Confirm its status | Szombathely | Hungary | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.